Adjuvant_chemotherapy_enhances_long-term_survival_of_patients_with_advanced_gastric_cancer_following_curative_resection._We_examined_the_effectiveness_of_postoperative_adjuvant_chemotherapy_with_mitomycin_C_(MMC),_1-(2-tetrahydrofuryl)-5-fluorouracil_(tegafur),_plus_PSK,_an_immunomodulator,_for_patients_with_advanced_gastric_cancer_who_underwent_histological_curative_resection._The_effect_of_chemotherapy_on_prognostic_serosal_(ps)_invasion_ps(-)_or_ps(+)_and_lymph_node_metastasis_n(-)_or_N(+)_was_examined._One_hundred_eighteen_patients_were_in_the_no-chemotherapy_group_and_137_were_on_the_drugs._The_median_follow-up_time_for_the_86_survivors_at_the_time_of_analysis_was_13.8_years._With_regard_to_prognostic_factors,_there_were_no_differences_between_the_two_groups._Generalized_Wilcoxon_test_of_the_two_survival_patterns_revealed_a_P_value_of_.0351,_and_the_survival_rate_for_15_years_was_45.7%_for_patients_in_the_no-chemotherapy_group_and_56.9%_for_those_of_the_chemotherapy_group._In_particular,_adjuvant_chemotherapy_was_effective_for_patients_with_ps(-)n(+)_(P_less_than_.05)_and_ps(+)n(-)_(P_less_than_.05),_but_not_for_those_with_ps(-)n(-)_and_ps(+)n(+)._Our_findings_show_that_the_concomitant_prescription_of_MMC,_tegafur,_and_PSK_improves_the_15-year_survival_rate_for_patients_with_advanced_gastric_cancer,_following_curative_resection._As_the_survival_rate_is_low_for_the_patients_with_ps(+)n(+),_an_even_more_aggressive_postoperative_chemotherapy_is_recommended.